News
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...
The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...
Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results